Niklas Prager appointed new President and CEO of Medivir

Stockholm, Sweden — Medivir AB (OMX: MVIR) today announces that the company’s
Board of Directors has appointed Niklas Prager as new President and CEO of
Medivir AB effective 1 September 2014. Niklas Prager will succeed Maris
Hartmanis who, as previously announced, leaves the position of President and CEO
of Medivir.

Niklas Prager holds a Degree of Master of Science in Business Administration and
Economics from the Stockholm School of Economics, and has held a variety of
different positions, mainly in the pharmaceutical industry, throughout his
career. Niklas has long experience from both high-growth research- and
technology-based companies as well as major international pharmaceutical
companies. His previous positions include working for Merck & Co. Inc. both in
the US and Sweden and serving as the CEO of Pfizer AB, Envirotainer AB and
Qbtech AB.

Niklas is thoroughly familiar with Medivir’s operations, having earlier served
as Chairman of the Board of BioPhausia, and he was elected to the Board of
Medivir in May 2014.

”I am delighted to welcome Niklas to the position of CEO of Medivir,” says
Birgitta Stymne Göransson, Chairman of the Board of Directors of Medivir. ”The
Board has carried out an extensive recruitment process during the spring which
involved several highly qualified candidates. Niklas has a background in both
biotech and big pharma, and his large network of contacts in the Swedish and
international pharmaceutical industries make him an ideal choice for us. Niklas
will in particular be able to contribute and strengthen Medivir in the important
areas of strategic business development and commercialisation.”

“I look forward to taking up the position as CEO of Medivir,” says Niklas
Prager. ”Medivir is an attractive company in an exciting phase of its
development following the successful market introduction of simeprevir. Together
with the Board, the highly skilled research team and all other Medivir
employees, I will be focusing on further value creation and enhanced visibility
of Medivir’s potential. An update of Medivir’s strategic plan is the number one
priority, and work on this is already well under way.”

As Niklas Prager takes up the position of CEO of Medivir he will be leaving the
company’s Board of Directors. He will also be offered to participate in
Medivir’s Long Term Incentive Program for 2014.
The Board would like to take this opportunity to thank Maris Hartmanis and
express its appreciation for his work as Medivir’s President and CEO since 2011.

For further information, please contact:
Birgitta Stymne Göransson, Chairman of the Board, mobile: +46 70 622 4303.
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292.

Medivir is required under the Securities Market Act to make the information in
this Press Release public. The information was submitted for publication at
08.30 CEST on 11 August 2014.

About Medivir
Medivir is an emerging and profitable research-based pharmaceutical company with
an established marketing and sales organisation in the Nordic region with a
broad portfolio of prescription pharmaceuticals. Medivir receives royalties from
Johnson & Johnson’s global sales of the hepatitis C pharmaceutical, Olysio.
In addition, revenues for sales of Olysio in the Nordic region are generated
through the company’s own sales and marketing organisation. Medivir’s research
and development portfolio of pharmaceuticals is based on the company’s expertise
within polymerase and protease drugs targeting different disease areas. The
company’s current research and development is focused on infectious diseases,
bone related disorders, neuropathic pain and oncology. Medivir is listed on the
NASDAQ OMX Stockholm Mid Cap List.